Back to Search Start Over

Poor Medication Access as a Driver of Excess Heart-Failure Readmissions Among Patients Living in Economically Deprived Neighborhoods.

Authors :
Gangavelli A
Liu Z
Wang J
Okoh A
Steinberg RS
Patel K
Patel SA
Dickert NW
Morris AA
Source :
Journal of cardiac failure [J Card Fail] 2024 Jul; Vol. 30 (7), pp. 947-951. Date of Electronic Publication: 2024 Mar 06.
Publication Year :
2024

Abstract

Background: Patients residing in socioeconomically deprived neighborhoods experience higher hospital readmission rates after hospitalization for heart failure (HF). The role of medication access in the excessive readmissions in this group is poorly understood. This study explored patients' perspectives on medication access by individuals living in socioeconomically deprived neighborhoods who had experienced HF readmission.<br />Methods: We conducted semistructured in-depth interviews with 25 patients (mean age 61 ± 9 years, 96% Black, 40% women) who were readmitted with acute HF at Emory Healthcare hospitals and were living in highly deprived neighborhoods (top decile of the Social Deprivation Index). Qualitative descriptive analyses of the interviews were performed by using a multilevel coding strategy.<br />Results: Most patients (84%) highlighted medications as a driver of HF readmission. Patients' reported reasons for lack of medication access included medication costs (60%), having access to refills only through an emergency department or hospitalization (36%), limited access to transportation (12%), and limited understanding of medications' role in disease management (12%).<br />Conclusion: Lack of access to medications for patients with HF who live in socioeconomically distressed neighborhoods exacerbate excess hospitalizations in this vulnerable population. This study focuses on patients' perspectives and experiences and identifies some potentially high-value areas to focus on in trying to enhance access and adherence to evidence-based therapies.<br />Competing Interests: Disclosures AAM reports consulting fees from Abbott, Acorai, BI Lilly, Cytokinetics, Edwards Lifesciences, Ionis, Merck, and Regeneron. NWD reports consulting and research funding from Abiomed.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1532-8414
Volume :
30
Issue :
7
Database :
MEDLINE
Journal :
Journal of cardiac failure
Publication Type :
Academic Journal
Accession number :
38458485
Full Text :
https://doi.org/10.1016/j.cardfail.2024.02.016